Fuda Franklin, Chen Weina
Department of Pathology, University of Texas Southwestern Medical Center, BioCenter EB3.234, 2330 Inwood Road, Dallas, TX, 75390-9317, USA.
Curr Hematol Malig Rep. 2018 Dec;13(6):455-466. doi: 10.1007/s11899-018-0479-1.
Minimal or measurable residual disease (MRD) detected by multiparameter flow cytometry (MFC) is an independent prognostic indicator in acute leukemia. However, the predictive value of MFC MRD is affected by technical challenges, interpretive complexities, and inadequate standardization, particularly in acute myeloid leukemia (AML). Here, we critically review the methodological principles of the MFC MRD assay and discuss clinical implications of MRD.
Key components of MFC MRD assays to be discussed include the principles of MFC, panel selection, analysis approaches, level of quantifiable MRD and calculation, reporting, and areas of improvements. Key components of clinical implications include context-dependent detection threshold and the integral role of MRD assessment by MFC in the era of ever-expanding molecular testing. With advancements in technology and standardization, MFC along with molecular assays will continue to play an important role in MRD assessment to evaluate treatment response and risk stratification.
通过多参数流式细胞术（MFC）检测到的微小残留病（MRD）或可测量残留病是急性白血病的独立预后指标。然而，MFC MRD的预测价值受到技术挑战、解释复杂性和标准化不足的影响，尤其是在急性髓系白血病（AML）中。在此，我们对MFC MRD检测的方法学原理进行批判性综述，并讨论MRD的临床意义。
将讨论的MFC MRD检测的关键组成部分包括MFC原理、抗体组合选择、分析方法、可量化MRD水平及计算、报告以及改进领域。临床意义的关键组成部分包括依赖背景的检测阈值以及在分子检测不断扩展的时代MFC进行MRD评估的重要作用。随着技术和标准化的进步，MFC与分子检测将继续在MRD评估中发挥重要作用，以评估治疗反应和风险分层。
